Release Date: March 31, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Eric, in terms of guidance, based on what you guys are providing, it kind of implies flattish growth every year. Would you have a sense of what the core revenue growth is contemplated in terms of your guidance for 2025? A: It's all core now, so $29.1 million core going to $29 to $32 million.
Q: Are there sapphire trade-ins taking place, or should we expect continued placements of Stratus? What might the net install base look like? A: We are focusing on routine use customers, which are 118 exiting 2024. We will continue to report the install base of optical genome mapping systems but won't guide to it due to potential trade-ins and other factors. The focus will be on revenue per customer rather than the number of systems installed.
Q: What has been the early feedback on the Stratus compute launched in collaboration with Nvidia, and how do you expect it to drive utilization for core customers? A: The feedback is positive. Stratus compute is compatible with the Stratus system, and we have software updates planned to improve its speed. We aim to continuously update and advance our software to meet customer demands for speed and efficiency.
Q: With the focus on customer acquisition, are there areas where you plan to acquire new customers that may have a lower cost of acquisition or higher utilization? A: Yes, we expect growth in the routine user group, particularly in Europe and the US. The effectiveness of the CPT code as of January 1st could be a catalyst for new sites. We will focus on leveraging published data and success stories from routine use sites.
Q: Regarding the Category One CPT code, is it application-specific, or could it be applied across any use of OGM? A: It is specific to the use of optical genome mapping in hematologic malignancies. It does not apply to other applications like constitutional genetic disorders, which may use PLA codes or bill as a reflex to standard tests.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.